# Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada

> **NCT01415401** · PHASE4 · COMPLETED · sponsor: **Alcon Research** · enrollment: 57 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension
- Open-angle Glaucoma

## Interventions

- **DRUG:** Brinzolamide 1% / timolol 0.5% maleate fixed combination

## Key facts

- **NCT ID:** NCT01415401
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2014-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01415401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01415401, "Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01415401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*